The Ministry of Health will be launching the second phase of the Saskatchewan Biosimilars Initiative in February 2026. This phase builds on the progress of the first phase of the Biosimilars Initiative, which was successfully completed in April 2024, and will continue to promote the use of biosimilar medications.
Under the Biosimilars Initiative, patients receive Saskatchewan Drug Plan coverage for a biosimilar version of their biologic medication where one is available and listed on the Saskatchewan Formulary. Biosimilars present a significant opportunity for cost savings and long-term health system sustainability while providing safe and effective medication options. Continued expansion of the Biosimilars Initiative supports patient access to public drug plan coverage.
For more information, visit: